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Abstract
The relationship between benign uterine leiomyomas and their malignant counterparts, i.e. leiomyosarcomas and smooth
muscle tumors of uncertain malignant potential (STUMP), is still poorly understood. The idea that a leiomyosarcoma could
derive from a leiomyoma is still controversial. Recently MED12 mutations have been reported in uterine leiomyomas. In this
study we asked whether such mutations could also be involved in leiomyosarcomas and STUMP oncogenesis. For this
purpose we examined 33 uterine mesenchymal tumors by sequencing the hot-spot mutation region of MED12.W e
determined that MED12 is altered in 66.6% of typical leiomyomas as previously reported but also in 11% of STUMP and 20%
of leiomyosarcomas. The mutated allele is predominantly expressed in leiomyomas and STUMP. Interestingly all classical
leiomyomas exhibit MED12 protein expression while 40% of atypical leiomyomas, 50% of STUMP and 80% of
leiomyosarcomas (among them the two mutated ones) do not express MED12. All these tumors without protein
expression exhibit complex genomic profiles. No mutations and no expression loss were identified in an additional series of
38 non-uterine leiomyosarcomas. MED12 mutations are not exclusive to leiomyomas but seem to be specific to uterine
malignancies. A previous study has suggested that MED12 mutations in leiomyomas could lead to Wnt/b-catenin pathway
activation however our immunohistochemistry results show that there is no association between MED12 status and b-
catenin nuclear/cytoplasmic localization. Collectively, our results show that subgroups of benign and malignant tumors
share a common genetics. We propose here that MED12 alterations could be implicated in the development of smooth
muscle tumor and that its expression could be inhibited in malignant tumors.
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Introduction
Smooth muscle tumors (SMT) are the most common mesen-
chymal tumors of the uterus. They encompass leiomyomas (LM),
atypical LM, Smooth muscle Tumor of Uncertain Malignant
Potential (STUMP) and leiomyosarcomas (LMS) [1–3]. LM are
benign tumors that represent 70% of hysterectomy specimens for
non-cancer related conditions in non-menopausal women. Atyp-
ical LM is a LM variant with atypical, unusual nuclei with spotty
distribution [4]. STUMP tumors represent a heterogeneous group
of rare tumors that cannot be histologically diagnosed as
unequivocally benign or malignant, according to the World
Health Organization classification [1–3]. Uterine LMS are
aggressive tumors with a poor prognosis overall, representing
40% of uterine sarcomas and 1–3% of uterine malignancies. The
histological distinction between benign and malignant SMT is
based on a tree-feature morphological approach encompassing
atypia, necrosis and mitotic count proposed in 1994 by Standford
investigators [4]. Only a few publications on STUMP and atypical
LM are available and they represent a critical problem for
pathologists and clinicians at the diagnostic and therapeutic levels
respectively. Some studies have tested histological and immuno-
histochemical tools (Ki-67, BCL2, p16 and p53) [5–6] to improve
diagnostic process and to evaluate the prognosis of such lesions but
unfortunately without clinical utility. Currently LMS are still
devoid of therapeutic targets.
The pathogenesis of SMT is poorly understood. It is generally
believed that uterine LMS arise de novo rather than from any
precursor lesions. Nevertheless, some cases of LMS deriving from
a pre-existing LM have been described [7–15]. Currently, little
data is available concerning genetic events that could be
implicated in LM development. A few, not specific, genetic
alterations occurring infrequently (in around 20% of LM) have
been described (chromosome 7q partial deletions, chromosome
12 trisomy, rearrangements of 12q14–15, 6p21–23 for example)
(reviewed in [16]). Recently Makinen et al. reported recurrent and
frequent Mediator complex subunit 12 (MED12) mutations in uterine
LM [17]. Makinen et al.’s study is the first report of such frequent
alterations identified in 70% of LM. All mutations are located in
the intron 1 and exon 2 of MED12 (6.2% and 64.4% respectively)
and are assumed to be activating mutations. The Mediator
complex consisting of 26 subunits, seems to be implicated in
transcription regulation and act as a bridge between DNA binding
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complex as reviewed in [18–19]. A subcomplex of the Mediator
complex, named CDK8 submodule, has been identified and is
composed of CDK8, MED12, MED13 and Cyclin C. Several
studies have suggested that this subcomplex can either activate or
repress transcriptional expression depending on the cellular
context as reviewed in [18–19].
In the present study, we thus asked whether MED12 mutations
could also be involved in oncogenesis of LM malignant
counterparts, i.e. LMS and STUMP. To extend the analyses we
also assessed MED12 expression at mRNA and protein levels and
studied tumor genomic profiles and b-catenin localization
according to MED12 alterations.
Results
Are MED12 mutations exclusive to human uterine
leiomyomas?
To assess this issue we sequenced the mutation hot-spot region
of MED12 described by Makinen et al [17] in 33 uterine tumors
including nine LM, five atypical LM, nine STUMP and ten LMS.
These tumors came from 32 individual patients. All sequences
were interpretable and we detected nine mutations (27%)
summarized in Table 1 and Figure 1. All tumors displayed only
one mutation and all MED12 mutations are heterozygous as
described by Makinen et al. [17].
Regarding typical leiomyomas, we observed six mutations (6/9:
66.6%), among them five point mutations (83.3%) and one nine-
base-pair (bp) deletion (16.7%). All point mutations were located
in codon 44 (exon 2) and were missense mutations. Typical LM
was the most frequently mutated entity, whereas no mutation was
detected in atypical LM. Of note, one STUMP (1/9: 11%) (27bp
in-frame deletion) and two uterine LMS (2/10: 20%) (point
mutations) were mutated. The two point mutations observed in
LMS also concerned the codon 44 and the deletion observed in
STUMP encompassed this region (deletion of codons 41 to 49).
These results indicate not only that MED12 is frequently mutated
in typical LM (66.6%), but also that mutations are not restricted to
benign tumors since one STUMP and two highly aggressive LMS
were mutated.
Are MED12 mutations exclusive to human uterine
smooth muscle tumors?
Given the identification of MED12 mutations in uterine LMS,
we asked whether MED12 mutations could also be observed in
LMS from internal trunk and limbs. Consequently, 38 additional
non-uterine LMS were submitted to MED12 sequencing and no
mutations were detected. These results tend to show that even if
MED12 mutations are not restricted to benign tumors, they seem
to be specific to uterine smooth muscle tumors.
Which MED12 allele is expressed?
Over the last 50 years, it has been extensively demonstrated that
in females normal cells X-chromosomal genes present a mono-
allelic expression due to random inactivation of one of the two X
chromosomes [20]. Given that the MED12 gene is located on the
X chromosome (Xq13.1) and that all genomic mutations observed
are heterozygous, we sequenced cDNA from all studied cases with
good enough RNA quality (69/71) to check which allele is
expressed.
In typical leiomyomas, all mutations identified at the genomic
level were observed on cDNA (Figure 2). Moreover, in all cases the
mutated allele seems to be predominantly expressed (LM1/4/6–8)
or seems to be the only one expressed (LM5). We observed the
same expression profile for the mutated STUMP (STUMP1).
Indeed, only the 27 bp deleted allele seems to be expressed.
Figure 3A presents the RT-PCR products obtained for all
uterine tumors studied. We observed that all classical LM express
MED12 (Figure 3A), whereas one atypical LM (LM11, 1/5: 20%)
does not exhibit MED12 expression. b-2-microglobulin control
shows a RT-PCR product for all cases (Figure 3A). In the same
manner, two STUMP do not express MED12 (STUMP5 and
STUMP7, 2/9: 22.2%). Concerning uterine LMS, no RT-PCR
products for MED12 could be observed in five cases (LMS1 to
LMS4 and LMS10, 5/10: 50%). Further, among the five LMS
without MED12 expression there are the two mutated uterine
LMS (LMS1 and LMS2).
In order to assess if this MED12 expression loss could also be
observed in LMS from internal trunk and limbs, we performed
MED12 RT-PCR on 36 non-uterine LMS for which frozen
material was available (Figure 3B). We observed that all 36 studied
LMS display MED12 expression. Inhibition of MED12 expression
seems to be specific to a subgroup of uterine malignant tumors
(STUMP and LMS).
Is MED12 protein expressed in uterine tumors?
In order to confirm MED12 mRNA expression results at the
protein level we performed an immunohistochemistry study. Our
results show that all classical LM expressed MED12 protein
(Figure 4 and Table 2). In these tumors MED12 is expressed
regardlessofitsmutationalstatus.Incontrast,weobservedthat40%
of atypical LM (2/5), 50% of STUMP (4/8) and 80% of LMS (8/
10) do not exhibit MED12 protein expression. All cases with no
MED12 mRNA do not present protein expression; those with a
slight positivity at the mRNAlevel exhibit the samenegative protein
profile and all atypical LM and STUMP with mRNA positivity
expressed the protein. Collectively these results not only confirmed
mRNAdata butalso showedthat two LMS (LMS5andLMS6) with
mRNA expression do not express MED12 protein.
Are MED12 alterations associated with peculiar genomic
profiles?
A recent study has shown that 82.6% of mutated LM do not
exhibit genomic alterations and that the remaining 17.4% present
Table 1. Summary of MED12 mutations observed in the series
of 33 uterine tumors.
Tumor
name Location Mutation
Nucleotide
change
Predicted
protein
change
LM1 Exon 2 G.A c.131G.A p.G44D
LM4 Exon 2 G.A c.131G.A p.G44D
LM5 Exon 2 G.T c.130G.T p.G44C
LM6 Exon 2 G.A c.130G.A p.G44S
LM7 Exon 2 G.A c.130G.A p.G44S
LM8 Exon 2 9 bp del c.126_134del9 p.K42_F45delinsN
STUMP1 Exon 2 27 bp del c.122_148del27 p.V41_P49del
LMS1 Exon 2 G.T c.131G.T p.G44V
LMS2 Exon 2 G.T c.130G.T p.G44C
WT: wild-type, MUT: mutated, bp: base-pair, LM: leiomyoma, STUMP: Smooth
muscle Tumor of Uncertain Malignant Potential, LMS: leiomyosarcoma.
doi:10.1371/journal.pone.0040015.t001
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shown that MED12 alterations are equally distributed among
karyotypically normal LM (69%) and uterine leiomyomas with
some rearrangements (63%) [22]. In order to ask in our series
whether MED12 alterations could be associated with peculiar
genomic profiles we performed array-CGH analysis.
Genomic profiles of representative mutated tumors are
presented as an example in Figure 5A. All mutated LM present
no alterations as is the case for all classical non-mutated LM. The
mutated STUMP exhibits a similar profile, whereas the two
mutated LMS show lots of chromosome gains and losses. We
could thus see that the mutated tumors exhibit the features
previously described for their respective histotype [23–24]. When
we looked at the tumor genomic profiles according to MED12
expression data, we observed that all tumors with no MED12
protein expression exhibit very rearranged genomic profiles. (For
example: Figure 5A (LMS1 and LMS2) and Figure 5B). In
contrast, wild-type tumors with MED12 expression exhibit no or
very few alterations except for LMS7 and LMS9 which are
rearranged tumors, as for other LMS.
Could MED12 play a role in LM oncogenesis through the
b-catenin/Wnt pathway?
Makinen et al.’s study has suggested a role of MED12 mutations
in LM through Wnt/b-catenin pathway activation [17] and it has
been shown that MED12 is implicated in transcription activation
of Wnt target genes by interacting with b-catenin [25–26]. We
thus assessed the b-catenin expression profile by immunohisto-
chemistry in this uterine tumor series in order to see if the Wnt/b-
catenin pathway was activated in these tumors, and if MED12
alterations were associated with a peculiar b-catenin pattern. We
first observed that none of the tumors exhibited nuclear b-catenin,
56.25% of tumors show a membranous staining (18/32), 18.75%
present both membranous and cytoplasmic labelings (6/32),
12.5% show only cytoplasmic b-catenin (4/32), and 12.5% are
negative for b-catenin (4/32) (Figure 6 and Table 2).
Considering the b-catenin staining in each histotype separately,
we saw that 66.6% of classical LM (6/9), 80% of atypical LM (4/
5), 87.5% of STUMP (7/8) and 70% of LMS (7/10) display a b-
catenin membranous localization. In contrast, a positive cytoplas-
mic b-catenin labeling, associated or not with a membranous
staining, is only observed in 22.2% of classical LM (2/9), 20% of
atypical LM (1/5), 37.5% of STUMP (3/8) and 40% of LMS (4/
10).
To go further in our analysis, looking at the b-catenin
localization pattern according to the MED12 status, we could
observe that 71.4% (5/7) of mutated tumors with MED12
expression display only membranous b-catenin and the remaining
28.6% (2/7) do not show b-catenin expression. The two mutated
LMS without MED12 expression both display a membranous
staining associated for one of them with a cytoplasmic labeling.
Finally concerning the wild-type tumors without MED12 expres-
sion, all staining profiles could be observed: 16.7% negative (2/12),
16.7% membranous and cytoplasmic, 25% cytoplasmic (3/12) and
41.6% membranous (5/12). Together, this data suggests that there
is no association between MED12 mutations and cytoplasmic or
nuclear b-catenin localization.
Figure 1. MED12 genomic mutations. Sequence chromatograms showing MED12 mutations observed on genomic DNA in the nine mutated
uterine LM, STUMP and LMS (Sequence viewer: FinchTV, Geospiza). Arrows indicate mutation sites.
doi:10.1371/journal.pone.0040015.g001
MED12 Alterations in Uterine Soft Tissue Tumors
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e40015Discussion
Currently the relationship between benign uterine tumors
(leiomyomas) and their malignant counterparts, i.e. leiomyosarco-
mas and STUMP, is still poorly understood. The idea that a LMS
could derive from a LM is still controversial. Indeed, the large
discrepancy in their frequency of occurrence (leiomyosarcomas
represent only 0.1 to 0.3% of leiomyomas [9]) could lead to
thinking that malignant transformations of LM if they exist are
very rare. Up until now, most cases of uterine LMS have been
believed to arise de novo, although several cases of uterine LMS
arising in pre-existing LM have been reported [7–12]. In the same
manner, some studies have hypothesized that, in the case of LMS
with a benign leiomyomatous area, the benign component could
be a precursor lesion to LMS [13–15]. All these issues could be
conciliated by the hypothesis which suggests that only a subset of
LM, with variant histological features and/or genomic alterations,
have potential for malignant progression, and that these peculiar
LM may represent a premalignant transitional state, while most
LM have no malignant potential as reviewed in [16].
Recently, recurrent mutations of the Mediator Complex Subunit 12
gene (MED12) have been identified in 70%, 58.8%, 67,6% and
52.2% of LM [17,21–22,27]. In the present study we have assessed
MED12 gene status in 33 uterine tumors including nine LM, five
atypical LM, nine STUMP and ten LMS, and we show not only
that 66.6% of LM present MED12 mutations, confirming previous
results, but also that 11% of STUMP and 20% of uterine LMS
present MED12 mutations. In this series all mutations concerned
the MED12 intron1-exon 2 hot-spot region previously described
[17,21–22,27]. Our results show more codon 44 mutations
(83.3%) than observed by Makinen et al. (49%) and Je et al.
(66.6%), fewer than observed by Markowski et al. (95.8%) but are
closed to those of McGuire et al. (89.5%). These discrepancies
could be due to the various sizes of the series (9, 67, 225, 80 and
148 LM respectively), but more probably to the tumor sampling.
Indeed in the present series the nine LM came from nine
individual patients as for McGuire et al. series which contained
only individual samples while in Makinen et al.’s series the 225 LM
derived from 80 different patients, and in Markowski et al.’s series
the 80 LM came from 50 distinct patients. We did not observe any
codon 36 or 43 point mutations and no intron 1 mutations in our
series, which are three other mutated regions identified by
Makinen et al. The two deletions in our series (9 bp in LM8 and
27 bp in STUMP1) are in-frame as all reported insertions-
deletions [17,21–22,27]. The 27 bp deletion was previously
described by McGuire et al. [22], and the 9 bp deletion has not
been already published [17,21–22,27]. Both deletions encompass
the codons 43 and 44.
In our study we observed two uterine leiomyosarcomas
exhibiting a MED12 mutation. Recently Je et al. have published
a mutational study of MED12 in 1862 samples, including
leiomyomas, diverse carcinomas, leukemias, sarcomas and other
stromal tumors, in which they observed only one malignant tumor
with a MED12 mutation [27]. Among the studied tumors, there
were five uterine LMS and the authors observed no MED12
mutation in these samples as in other sarcomas. These discrep-
ancies may be due to the sampling size indeed in our study we
observed a MED12 mutation only in 20% of uterine LMS.
According to Je et al. results combined to ours it appears that
MED12 mutations are not exclusive to benign malignancies and
Figure 2. MED12 mutations on cDNA. Sequence chromatographs of MED12 mutations observed on cDNA showing that the mutated allele is
predominantly expressed. Arrows indicate mutation sites.
doi:10.1371/journal.pone.0040015.g002
MED12 Alterations in Uterine Soft Tissue Tumors
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malignant tumors.
The first point thus assessed here is the potential filiation
between benign and malignant uterine tumors. Our results show
that mutations are not restricted to benign tumors since two highly
aggressive LMS (20%) and one STUMP (10%) are mutated.
At least two mechanisms could explain the occurrence of
MED12 mutations in the three entities (LM, STUMP and LMS):
either common genetics at the initial developmental steps, or
mutated STUMP/LMS were first LM then subsequently acquired
alterations leading to malignant evolution. The second hypothesis
is consistent with the previously mentioned hypothesis which
proposed that a subgroup of LM could undergo malignant
transformation and could thus evolve in LMS [7–15]. However no
such conclusions could be made for the non-mutated uterine LMS
on the basis of this data.
We also investigated MED12 allele expression by RT-PCR,
sequencing and immunohistochemistry. All typical leiomyomas
expressed MED12 at mRNA and protein levels and in mutated
LM it seems that the mutated allele is predominantly expressed, as
described previously [17,21–22]. For cases with a minor wild-type
transcript expression, we could hypothesize that it may be due to
normal cell contamination. However, we could not exclude a
MED12 wild-type allele expression for a minority subclone of the
tumor. Indeed, many studies have described a clonal origin of LM
[28–31] but one study has shown that some LM could be
heterogeneous [32]. Concerning tumors with intermediate or high
malignancy we observed that 40% of atypical LM, 50% of
STUMP and 80% of LMS do not express MED12 protein.
Among these 14 tumors with no MED12 protein 57.1% (8/14) do
not exhibit mRNA, 28.6% (4/14) show a weak RT-PCR positivity
and 14.3% (2/14) express mRNA. According to array-CGH
Figure 3. MED12 RNA expression. (A) Expression profiles of MED12 and b2M (b-2-microglobulin) obtained by RT-PCR in uterine smooth muscle
tumors are presented. b2M is used as RT-PCR control. (B) Expression profiles of MED12 and b2M (b-2-microglobulin) obtained by RT-PCR in LMS from
limbs and internal trunk are presented. *: mutated tumors. L: molecular weight ladder. LM: leiomyoma, LMS: leiomyosarcoma, STUMP: Smooth muscle
Tumor of Uncertain Malignant Potential.
doi:10.1371/journal.pone.0040015.g003
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MED12 expression loss is not due to a deletion of the MED12
allele on the active X chromosome. In tumors with no mRNA and
no protein, MED12 should thus be transcriptionally inhibited. To
our knowledge, no data concerning MED12 expression regulation
is currently available so we could only hypothesize that its
expression could be inhibited by promoter or histones methyla-
tion, or that a transcriptional repressor of MED12 could be
expressed in these tumors. Concerning tumors with few mRNA we
could do the same hypothesis if the weak positivity is supposed to
be due to normal cell contamination. We could also hypothesize
that the absence of MED12 protein in tumors with mRNA
positivity could be due to post-transcriptional or translational
inhibition by miRNA for example. According to the TargetScan
microRNA target prediction algorithm [33] MED12 3’UTR
presents potential target sites for miRNAs.
Interestingly concerning uterine LMS, MED12 expression
seems to be inhibited regardless the allele status. Indeed for the
two mutated LMS, we could not know if the MED12 mutation
occurred on the inactivated X chromosome and if the second wild-
type allele was transcriptionnally inactivated or if it’s the activated
X allele which was mutated and then subsequently inhibited.
However, collectively these results show that MED12 may be
implicated in the early steps of both benign and malignant uterine
tumor development, its expression being inhibited in a subset of
tumors, those with malignant potential.
Array-CGH data show that the inhibition of MED12 expression
is associated with malignant tumors. Actually, benign tumors are
generally associated with simple genomic profiles [23,34–36],
whereas most malignant tumors exhibit much altered profiles and
these are tumors in which the number and type of genetic
alterations are strong prognostic factors [37–38]. In uterine
smooth muscle tumors it has been described that uterine LMS,
as LMS from internal trunk and limbs, exhibit highly rearranged
genomic profiles, while LM present no or few alterations detected
by array-CGH [23–24]. In our series, all tumors that expressed
MED12 mutations exhibited no or very few genomic alterations.
The only two tumors with a MED12 mutation and a rearranged
genomic profile were LMS, which also exhibited complete MED12
expression inhibition. In the same manner, all tumors without
MED12 expression presented altered genomic profiles. As a result,
even if MED12 mutations are not restricted to tumors without
genomic alterations, it seems that inhibition of its expression is
specific to malignant rearranged uterine tumors. Thus, we could
hypothesize that MED12 mutations have been acquired before
malignant transformation. Its expression loss could occur later in
the malignant transformation process or could correspond to
another mechanism of MED12 inactivation specific of rearranged
tumors.
Makinen et al. have suggested based on bioinformatics pathway
analysis [17] that MED12 mutations could be involved in LM
development through activation of the Wnt/b-catenin pathway;
the Wnt/b-catenin target genes being among the genes positively
regulated by MED12 [25–26]. However a recent study combining
mRNA and miRNA differential expression between LM and
myometrium has observed a downregulation of the Wnt pathway
and an upregulation of the focal adhesion pathway in LM [39].
Our b-catenin immunohistochemistry data tends to indicate that
the canonical Wnt pathway is not implicated in LM development
since b-catenin, when expressed, is located to the membrane in
Figure 4. MED12 protein expression. (A) Positive MED12 nuclear labeling in mutated LM6. (B) Positive MED12 nuclear staining in wild-type
STUMP8. (C) Wild-type STUMP4 with negative staining (D) Mutated LMS1 without MED12 labeling. Magnification: X40.
doi:10.1371/journal.pone.0040015.g004
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demonstrated to be indicative of a low transactivation activity [40–
41]. The Wnt/b-catenin pathway does not seem constitutively
activated in these mutated tumors and we could thus hypothesize
that if MED12 mutations play a role in uterine tumor development
it’s probably not through Wnt target genes activation in
association with b-catenin. In order to precisely assess pathways
which could be activated by MED12 mutations it seems necessary
to compare expression profiles between mutated LM and non-
mutated LM.
When we consider each histotype separately, we see that
positive cytoplasmic b-catenin labeling, associated or not with
membranous staining, is observed in 22.2% of classical LM, 20%
of atypical LM, 37.5% of STUMP and 40% of LMS. This means
that even if the b-catenin membranous labeling is predominant in
all uterine tumors subtypes, the frequency of b-catenin cytoplasmic
localization tends to increase in parallel with tumor malignity.
These results suggest that the Wnt pathway could be implicated in
malignant progression, probably without MED12 involvement.
Data is scarce in the literature regarding the b-catenin localization
in uterine tumors but two studies previously reported no nuclear
staining [42–43], results consistent with ours. Conversely nuclear
b-catenin labeling has been previously observed in 23% of uterine
LMS, membranous staining in 25% of LMS and cytoplasmic
positivity in 36% of LMS [44]. Discrepancies between the studies
concerning LMS may be due to the size of the series (245 LMS
versus 10), to the antibody used or to the labeling interpretation. b-
Table 2. MED12 gene expression and b-catenin localization.
Tumor Name Histotype MED12 status
MED12 RNA
expression
MED12 IHC
staining
b-catenin IHC
localization
LM1 LM MUT Positive Positive Negative
LM2 LM WT Positive Positive M + C
LM3 LM WT Positive Positive C
LM4 LM MUT Positive Positive Negative
LM5 LM MUT Positive Positive M
LM6 LM MUT Positive Positive M
LM7 LM MUT Positive Positive M
LM8 LM MUT Positive Positive M
LM9 LM WT Positive Focal positivity M
LM10 Atypical LM WT Positive Positive M
LM11 Atypical LM WT Negative Negative Negative
LM12 Atypical LM WT Positive Focal positivity M
LM13 Atypical LM WT Positive Positive M
LM14 Atypical LM WT Slight positivity Negative M + C
STUMP1 STUMP MUT Positive Positive M
STUMP2 STUMP WT Slight positivity NA NA
STUMP3 STUMP WT Positive Positive M + C
STUMP4 STUMP WT Slight positivity Negative C
STUMP5 STUMP WT Negative Negative M
STUMP6 STUMP WT Positive Positive M
STUMP7 STUMP WT Negative Negative M + C
STUMP8 STUMP WT Positive Positive M
STUMP9 STUMP WT Slight positivity Negative M
LMS1 LMS MUT Negative Negative M + C
LMS2 LMS MUT Negative Negative M
LMS3 LMS WT Negative Negative Negative
LMS4 LMS WT Negative Negative M
LMS5 LMS WT Positive Negative M
LMS6 LMS WT Positive Negative M
LMS7 LMS WT Positive Focal positivity M
LMS8 LMS WT Slight positivity Negative C
LMS9 LMS WT Positive Positive M + C
LMS10 LMS WT Negative Negative C
Tumor histotype and MED12 mutational status are indicated. LM: leiomyoma, STUMP: Smooth muscle Tumor of Uncertain Malignant Potential, LMS: leiomyosarcoma.
WT: wild-type, MUT: mutated. MED12 mRNA (RT-PCR) and protein expression (IHC) are summarized. Finally b-catenin localization visualized by IHC in tumors is indicated.
M: membranous staining, C: cytoplasmic labeling. NA: not available.
doi:10.1371/journal.pone.0040015.t002
MED12 Alterations in Uterine Soft Tissue Tumors
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tumors.
Another question of great interest is the similarity between
uterine LMS and LMS from other locations. On the basis of our
results we have observed that LMS from internal trunk and limbs
do not exhibit MED12 mutations and that they all express
MED12. MED12 alterations seem to be specific to a subgroup of
uterine malignant tumors. MED12 expression loss may contribute
to the oncogenesis process of this subset of uterine tumors but not
to LMS from other locations, meaning that these tumors could be
two different entities or at least originating from distinct genetics
and/or cell types. It could be interesting to analyze in further
detail the two groups of uterine LMS, i.e. those with and those
without MED12 alterations, in order to see if they also represent
distinct entities and if the LMS group without MED12 alterations
is closer to the non-uterine LMS group than to the other uterine
group. In the same manner, it could be of great interest to study
non-uterine LM to see if MED12 alterations are really exclusive to
uterine tumors.
The role of MED12 in the oncogenesis process has not already
been assessed and it may be hard to determine because of its both
repressive and activating functions according to the cellular
context as reviewed in [18–19]. In Makinen et al.’s study,
MED12 mutations observed in LM are supposed to be activating
ones [17]. Substantial data supports this idea: the absence of
nonsense mutations, the presence of in-frame deletions and the
Figure 5. Tumor genomic profiles. (A) CGH profiles of four cases representing a leiomyoma (LM), a STUMP and the two mutated uterine
leiomyosarcomas (LMS). (B) CGH profiles of four representative cases without MED12 expression. Genomic alterations are presented and organized
from chromosome 1 to 22 and X, Y on the X axis and log2 ratio values are reported on the Y axis. Significant gains or losses are indicated by red lines
and red areas above or below each profile, respectively.
doi:10.1371/journal.pone.0040015.g005
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proposed the opposite hypothesis [22]. According to the
transcriptional repressive and chromatin modifying known func-
tions of MED12, they hypothesize that MED12 could be a tumor
suppressor gene, leading to abnormal leiomyomatous growth
when mutated. This hypothesis of tumor suppressor gene is
strengthened by our data showing that a subgroup of rearranged
tumors exhibits a loss of MED12 expression. We could thus
hypothesize that MED12 mutations modify or attenuate a function
of the protein leading to a benign proliferation and that only the
loss of all MED12 functions by expression inhibition could be
implicated in malignant transformation. This hypothesis is
supported by the fact that all mutations affect the same domain
of the gene; all deletions are in-frame and are expressed at mRNA
and protein levels suggesting that other domains of the protein
could still be functional in LM.
We report here the first MED12 mutations and expression
alteration in uterine LMS. It is now essential to validate our
hypotheses regarding the role of MED12 mutations in leiomyoma
development and MED12 inhibition in leiomyosarcomas onco-
genesis. To address these issues we plan to modulate MED12
expression in uterine LM and LMS cell lines. Further investiga-
tions, establishing murine models with specific knock-out of
MED12 in smooth-muscle cells as performed for example with
connexin 43 [45] as well as analyzing the impact of a MED12
mutated allele expression or a MED12 knock-out allele in
mesenchymal stem cells, fibroblasts or smooth-muscle cells may
be also useful to validate the model.
Materials and Methods
Ethics Statement
The samples used in this study as part of the Biological
Resources Center of Bergonie Cancer Institute (CRB-IB).
Accordance with the French Public Health Code (articles L.
1243-4 and R. 1243-61), the CRB-IB has received the agreement
from the French authorities to delivered samples for scientific
research (number AC-2008-812, on February 2011). These
samples are from care and requalified for research. The patients
signed a consent approved by the Committee of Protection of
Individuals.
Samples and histology
A retrospective series of 33 cases of uterine SMT (9 LM,
5 atypical LM, 9 STUMP and 10 LMS) collected in the
Department of Pathology of the Bergonie Cancer Institute in
Bordeaux was reviewed by two pathologists with interest in
gynecopathology (GMG and SC). According to Bell et al.’s criteria
[4], a SMT without atypia, without necrosis and low mitotic count
was diagnosed as LM (,5 mitosis/10 HPFs for epithelioid
variant, ,2 mitosis/10 HPFs for myxoid variant); atypical LM is
a LM variant with atypical, unusual nuclei with spotty distribution
and ,10 mitosis/10 HPFs. A SMT with important and diffuse
atypia and/or coagulative necrosis and high mitotic count was
classified as LMS. We made the diagnosis of STUMP in the
following histological patterns: 1) diffuse atypia (moderate to
severe) with mitotic rate #10 mitosis/10 HPFs without necrosis; 2)
focal atypia (moderate to severe) and .10 mitosis/10 HPFs
without necrosis; 3) no to mild atypia with $20 mitosis/10 HPFs
Figure 6. b-catenin expression. (A) Nuclear b-catenin labeling control in a desmoid tumor. (B) Leiomyoma without b-catenin expression (LM1). (C)
Uterine leiomyosarcoma with cytoplasmic b-catenin expression (LMS8). (D) Uterine leiomyosarcoma with membranous b-catenin expression (LMS2).
Magnification: X40.
doi:10.1371/journal.pone.0040015.g006
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[46]. These tumors came from 32 individual patients. STUMP3 is
the local recurrence of STUMP2. Clinical and pathological data
are presented in Table S1.
The 38 cases of nongynecological LMS were reviewed by a
pathologist expert in soft tissue sarcomas (JMC) according to the
World Health Organization recommendations [47]. These tumors
came from 38 individual patients. Clinical and pathological data
are presented in Table S2.
DNA and RNA extraction
For internal trunk LMS and LMS of the limbs, genomic DNA was
isolated using a standard phenol-chloroform extraction protocol on
frozen samples. For uterine SMT, which are paraffin-embedded
tissues, genomic DNA was extracted according to Agilent protocol for
DNA isolation on FFPE tissues (http://www.chem-agilent.com/pdf/
G4410-90020v3_1_CGH_ULS_Protocol.pdf) (Agilent Technologies).
For RNA extraction, paraffin was removed using two steps in
toluene followed by two steps in absolute ethanol. Samples were
then incubated over-night at 55uCi n2 0 0ml of ATL buffer (Qiagen
DNeasy Blood & Tissue Kit, Qiagen) and 20 ml of proteinase K.
Additional 10 ml of proteinase K were added twice the two next
days and samples were incubated as previously described. Total
RNA was then extracted using a standard TRIzol (Life Technol-
ogies)/chloroform extraction followed by an isopropanol precipita-
tion. Finally, genomic DNA and RNA were quantified using a
Nanodrop 1000 spectrophotometer (Thermo Scientific).
Mutation Screening
Mutation screening of MED12 exon2 was assessed on genomic
DNA and on cDNA. For cDNA sequencing, total RNA was first
reverse transcribed using High Capacity cDNA Reverse Tran-
scription Kit (Applied biosystems) according to the manufacturer’s
instructions. Primers used were designed using Primer 3 program
(http://frodo.wi.mit.edu/primer3/) and are presented in Ta-
ble S3. Pre-sequencing PCR was realized on 50 ng of genomic
DNA or cDNA using AmpliTaqGoldH DNA polymerase (Applied
Biosystems) with an annealing temperature of 60uC. PCR was also
realized using b2M (b-2-migroglobulin) primers as control
(Table S3). PCR products were then purified using ExoSAP-IT
PCR Purification Kit (GE Healthcare) and sequencing reactions
were performed with the Big Dye Terminator V1.1 Kit (Applied
Biosystems) according to the manufacturer’s recommendations.
Samples were then purified using the Big Dye XTerminator
Purification kit (Applied Biosystems) according to the manufac-
turer’s instructions and sequencing was performed on a 3130xl
Genetic Analyzer (Applied Biosystems). Sequences analysis was
performed with SeqScape software v2.5 (Applied Biosystems).
Mutations are referenced on the Wellcome Trust Sanger Institute
webpage as part of the COSMIC project (Catalogue Of Somatic
Mutations In Cancer) http://www.sanger.ac.uk/perl/genetics/
CGP/cosmic?action=mutations&ln=MED12&sn=soft_tissue&
hn=leiomyoma&start=1&end=2178&coords=AA:AA&neg=off&
page=1.
Array-CGH
Array-CGH experiments were thus realized for 30 cases with
good enough DNA quality. No array-CGH results are available
for LM11, STUMP2 and LMS3. DNA was first treated using a
DNase as previously described [48]. DNA was then hybridized to
8660K whole-genome Agilent arrays (G4450A) as previously
described [38]. Microarray slides were scanned using an Agilent
DNA Microarray Scanner, images were analyzed by Feature
Extraction V10.1.1.1 and then analyzed by Agilent Genomic
Workbench Lite Edition 6.5.0.18 (Agilent). The ADM-2 algorithm
was used to identify DNA copy number anomalies at the probe
level. A low-level copy number gain was defined as a log 2 ratio
.0.25 and a copy number loss was defined as a log 2 ratio
,20.25. A high-level gain or amplification was defined as a log 2
ratio .1.5 and a homozygous deletion was suspected when the
ratio was below 21.
Immunohistochemistry
Tissue sections were obtained from paraffin blocks. Immuno-
histochemistry was performed using a Benchmark Ultra automat-
ed stainer (Ventana), a beta-catenin antibody (manufacturer’s
dilution, Clone 14, 760–4242, Ventana) and a MED12 antibody
(dilution: 1/30, HPA003184-Ab1, Sigma) according to the
manufacturer’s recommendations. IHC pictures were taken using
a Leitz DMRB microscope (Leica) and a DS-Ri1 camera (Nikon).
Supporting Information
Table S1 Uterine smooth muscle tumors clinical and
pathologic data. Histotype, localization and size of the 33 SMT
are indicated in this table. Age of the patients at the diagnosis is
also mentioned. Data availability for the different techniques used
is indicated for each tumor. LM: leiomyoma; STUMP: Smooth
muscle Tumor of Uncertain Malignant Potential; LMS: leiomyo-
sarcoma; A: available; NA: not available.
(DOC)
Table S2 Non-uterine leiomyosarcomas clinical and
pathologic data. Localization and size of the 38 non-uterine
LMS are indicated in this table. Age and sex of the patients are
also mentioned. Data availability for the different techniques used
is indicated for each tumor. LMS: leiomyosarcoma; A: available;
NA: not available.
(DOC)
Table S3 Primers used. MED12 and b2-microglobulin
forward and reverse primers are presented.
(DOC)
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